2013 closed with the total venture financing value raised by Biotech companies in the U.K. being decreased by 47% compared to its 2012 level (USD 283m in 2013 compared to USD 530m in 2012). The number of U.K. biotech products (therapeutics and diagnostics) in the first stage of the clinical pipeline (Phase I) was increased by 7% this summer compared to the same period last year, while during the same period, the number of products in Phases II and III of development saw a sharp decrease of 21% and 17% respectively.
Click here to download UK Life Sciences Trend Analysis 2014 – 14 pages
Looking for your next Biotech or Medtech partner?
Use Biotechgate to identify new leads, licensing opportunities and management details.